Correspondence on: "Real-world safety data of first-line drugs for rheumatoid arthritis: insights from the Portuguese Reuma.pt database".
This correspondence addresses methodological considerations in a study analyzing adverse event (AE) reports from the Portuguese Reuma.pt registry on first-registered disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis (RA). It highlights the need for reporting exposure denominato...
| Publicado en: | ARP Rheumatology Vol. 5; no. 2; pp. 135 - 138 |
|---|---|
| Autores principales: | , |
| Formato: | Artículo |
| Publicado: |
Sociedade Portuguesa de Reumatologia
Apr-Jun2026
|
| Materias: | |
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=lth&AN=195258517&site=ehost-live header: @attributes: shortDbName: lth uiTerm: 195258517 longDbName: MedicLatina uiTag: AN controlInfo: bkinfo: jinfo: jid: 27954552 N2OK jtl: ARP Rheumatology issn: 27954552 maglogo: N pubinfo: dt: Apr-Jun2026 vid: 5 iid: 2 pid: 38819 pub: Sociedade Portuguesa de Reumatologia artinfo: ui: 195258517 10.63032/GMFT5342 ppf: 135 ppct: 3 formats: fmt: @attributes: type: P size: 199KB tig: atl: Correspondence on: "Real-world safety data of first-line drugs for rheumatoid arthritis: insights from the Portuguese Reuma.pt database". aug: au: Choudhuri, B. Prakash, J. affil: Department of Critical Care, Emergency Medicine & Rheumatology, Parkview Super-specialty Hospital, Kolkata, West Bengal, India. Department of Critical Care Medicine, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, India. su: Antirheumatic agents Medical registries Data quality Medical records Methotrexate Rheumatoid arthritis Drug utilization Adverse health care events sug: subj: Antirheumatic agents Medical registries Data quality Medical records Methotrexate Rheumatoid arthritis Drug utilization Adverse health care events ab: This correspondence addresses methodological considerations in a study analyzing adverse event (AE) reports from the Portuguese Reuma.pt registry on first-registered disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis (RA). It highlights the need for reporting exposure denominators (e.g., number of patients treated, patient-years), clarifying the definition of “first-line” therapy as used in the registry versus clinical guidelines, and standardizing seriousness and causality assessments according to established pharmacovigilance frameworks such as the WHO-Uppsala Monitoring Centre system. The authors also emphasize addressing missing data on key clinical covariates (e.g., methotrexate dose, comorbidities, concomitant medications) and suggest patient-level sensitivity analyses to avoid bias from multiple AE reports per individual. These recommendations aim to improve interpretability, reproducibility, and cross-cohort comparability of real-world safety data from Reuma.pt and similar registries. pubtype: Academic Journal doctype: Article src: R language: English refInfo: copyright: @attributes: flag: Y custom: Copyright of ARP Rheumatology is the property of Sociedade Portuguesa de Reumatologia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. item: ARP Rheumatology holder: Sociedade Portuguesa de Reumatologia dt: @attributes: year: 2026 holdings: @attributes: islocal: N |
|---|